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Metformin Impairs Endothelialization After Placement of Newer Generation
Drug Eluting Stents
Anwer Habib1, Rohini Polavarapu Rohini Polavarapu1, Vinit N. Karmali2,
Hirokuni Akahori1, Kim Pachura2, Aloke V. Finn3
1Emory University, Atlanta, GA, 2Emory University, Atlanta, GA, 3Emory, Altanta, GA
Background: Metformin may delay endothelialization of drug eluting stents
(DES) due to convergent signaling at the mammalian target of rapamycin
(mTOR) pathway. We aim to assess whether metformin will continue to
adversely affect stent endothelialization despite improvements in newer generation
DES.
Methods: Rabbit iliac artery stenting with newer generation DES was performed
followed by 14 days of oral metformin or placebo treatment. Scanning electron
microscopy was used to assess stent endothelialization after sacriﬁce.
Results: In the metformin-treated group there was signiﬁcantly less endothelialization
compared to the placebo-treated group. Paclitaxel-eluting stents in placebo-treated
group had the least delay in endothelialization with signiﬁcantly greater delay in both
its metformin-treated counterpart and all –limus eluting stent groups (ﬁgure 1).
Representative scanning electron micrographs (15x) of 14-day paclitaxel eluting stents
(PES), everolimus- and zotarolimus-eluting stents (EES, ZES) in the presence or
absence of oral Metformin (100 mg/kg/day) treatment (ﬁgure 1A) with quantiﬁcation
shown (Figure 1B, groups under the line representing p < 0.05 compared with PES-
control with at least 4 animals per group).Conclusions: Metformin inhibited stent endothelialization in newer generation DES
likely through convergent and divergent mechanisms. By delaying stent endothelial-
ization, metformin may increase the risk for thrombotic complications after DES
placement.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-794
Intracoronary Infusion of Bone Marrow Mesenchymal Stem Cells in Acute
Myocardial Infarction- A Critical Challenge for Dosage-Related Efﬁcacy and
Safety
lian R. Gao1, Yu Chen1, Qing A. Ding2, Feng Guo1, Tian C. Li3, Hui L. Liu4,
Xue T. Pei5, Zi C. Tong6, Ning K. Zhang1, Zhi M. Zhu1
1Navy General Hospital, Beijing, China, 2Center of Cardiology, Navy General
Hospital, Beijing, China, China, 3Beijing Tongren Hospital, Beijing, China, 4Armed
police general hospital, Beijing, China, 5Academy of Military Medical Sciences,
Beijing, Chile, 6Beijing Chaoyang Hospital, Beijing, China
Background: To date, there have been debates on the risk and efﬁcacy of bone
marrow mesenchymal stem cell (BMSC) therapy in patients with acute myocardial
infarction (AMI). This study aimed at testing whether BMSC intracoronary infusion
following revascularization has a beneﬁcial effect on the myocardium of AMI
patients. This study is registered with ChiCTR, number ChiCTR-TRC-08000080.
Methods: A single-blind, randomized multicenter trial was conducted in patients with
ST-elevation MI (STEMI, n¼43), (2008-2009). All the patients who had been
successfully reperfused within 12 hours were randomly assigned to receive an intra-
coronary infusion of BMSCs or optimum medical therapy after PCI. The primary
endpoint was the change in myocardial viability and perfusion within the infarcted
territory by 18-FDG/99mTc-sestamibi SPECT, and the change in global left
ventricular ejection fraction by 2D echocardiography.
Results: A mean of (3.080.52) x106 2nd passage MSCs were obtained from 80 ml
bone marrow after an average of 14.60.7 days in culture. BMSCs were transplanted
at an average of 17.10.6 days. Six months after cell transfer, myocardial viability
within the infarct area was improved in both groups compared with baseline, but
18-FDG SPECT showed no signiﬁcant difference between the BMSC and control
groups (4.0  0.4% 95%CI 3.1-4.9 vs. 3.2  0.5% 95%CI 2.1-4.3, P¼0.237).
Moreover, 99mTc-sestamibi SPECT demonstrated that myocardial perfusion within
the infarct area in patients receiving BMSCs did not differ from the control group
(4.40.5% 95%CI 3.2-5.5 vs. 3.90.6% 95%CI 2.6-5.2, P¼0.594). Similarly, LVEF
after 12, 24 months of followup also did not show any difference between the two
groups (12mon' LVEF: 4.50.7% 95%CI 3.0-6.1 vs. 3.20.7% 95%CI 1.7-4.6,
P¼0.182). In the BMSC group, one patient suffered a serious complication involving
coronary artery occlusion during the MSC injection procedure.
Conclusions: The clinical beneﬁts and the safety of intracoronary injection of
autologous BMSCs in acute STEMI patients need further investigation and
reevaluation.
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Pre-clinical analysis of safety and efﬁcacy of a new sirolimus eluting stent
compared with bare metal, everolimus and sirolimus eluting controls
Armando Pérez de Prado1, Claudia Pérez-Martínez1, Carlos Cuellas1,
Marta Regueiro1, María López-Benito1, Beatriz Martínez-Fernández1,
Luis Duocastella2, María Molina2, Isabel Pérez-Serranos2, Marc Amoros2,
Rodrigo Estevez1, Alejandro Diego1, José Manuel Gonzalo-Orden1,
Felipe Fernández-Vázquez1
1HemoLeon, Fundación Investigación Sanitaria en León, Leon, Leon, 2iVascular,
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Background: As requested by the regulatory agencies, new drug-eluting stents (DES)
must be tested in animal models before conducting clinical trials. This study analyzes
the antiproliferative efﬁcacy and the safety proﬁle (vascular healing) of new sirolimus
eluting stents (SES) as compared with their bare metallic backbone, bare metal stents
(BMS) and 2 different commercial DES, one SES and one everolimus-eluting stent
(EES).
Methods: In 12 young domestic pigs (253 kg), 36 stents were implanted: 11 SES
Test1, 10 SES Test2 (iVascular, Spain), 5 SES Cypher (J&J, USA), 5 EES Xience
(Abbott, USA) and 5 control BMS Architect (iVascular, Spain). The achieved
stent:artery ratio was 1.390.13. The efﬁcacy and safety results were analyzed at 28
days. We measured the angiographic % diameter stenosis and histologic % area
stenosis, as well as neointimal area. The vascular healing process was evaluated
through the semi-quantitative scores of vascular injury, inﬂammation, ﬁbrin, and the
rate of endothelialized luminal surface.
Results: The tested SES (Test1, Test2) and the control SES and EES showed
similar restenosis results, while the control BMS showed signiﬁcantly higher
restenosis values. All the stents showed low values of vascular injury, as demon-
strated by low global injury (0.90.5) and inﬂammation (10.5) scores, without
differences between groups. On the contrary, some signs of delayed vascular
healing (directly related to the pharmacological effect) as lower endothelialization
rate and persistent ﬁbrin deposition, are signiﬁcantly worse in DES (no differences
between groups) than in BMS.acts/POSTER/Basic Science, Animal Models, and Cell Therapy B241
BMS Cypher Xience SES Test1 SES Test2 p (DES vs. BMS)
Angiography
%stenosis 36  12 23  14 29  10 20  8 23  8 0.014
Histology
%stenosis 60  23 47  8 30  10 40  14 41  11 0.019
Neointimal
area mm2
3.9  0.6 3.3  0.9 1.9  0.8 2.5  0.6 2.4  0.6 0.006
Injury score 1.3  0.6 0.8  0.5 0.9  0.5 0.9  0.5 0.9  0.4 0.18
Inﬂammation
score
1.6  0.6 1.2  0.5 0.8  0.4 1.0  0.3 0.9  0.5 0.06
%
endothelialization
99  1 95  4 94  3 93  3 96  1 0.016
Fibrin score 0.1  0.2 1.7  0.5 1.4  0.4 1.3  0.6 1.2  0.5 0.003
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SES and EES, and signiﬁcantly less restenosis than BMS. All DES showed equivalent
levels of low endothelialization and higher ﬁbrin score than BMS, although the injury
and inﬂammation scores were similar in all groups.
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Safety and efﬁcacy of different paclitaxel-eluting balloons in a preclinical model
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Marta Regueiro1, María López-Benito1, Beatriz Martínez-Fernández1,
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Background: The drug-eluting balloons (DEBs) have demonstrated a high anti-
proliferative efﬁcacy in the treatment and prevention of restenosis. Nevertheless, not
all the available devices are equally effective; so, the comparison of the results in
a preclinical model is relevant. Our objective is to assess the preclinical efﬁcacy and
safety of different DEBs.
Methods: In 17 domestic swine (253 kg), we implanted 51 Cobalt-Chromium
metallic stents (Architect, iVascular, Spain), one stent per major coronary artery.
Stent postdilatation was performed with different balloons to achieve high stent-
artery ratios (1.21  0.14). We used bare control balloons (n¼10), Test1 (DEB
Essential, iVascular; n¼15), Test2 (Modiﬁed Essential -more hydrophilic matrix,
iVascular; n¼16), and commercial DEBs (In.Pact Falcon, Medtronic, USA;
n¼10). Restenosis values (%diameter stenosis, late loss by angiography and %area
stenosis, neointimal area by histomorphometry) and vascular healing parameters
(injury score, endothelialization rate, ﬁbrin and inﬂammation scores) were analyzed
at 28 days.
Results: All the DEBs showed similar stenosis values at follow-up, signiﬁcantly lower
than bare controls: angiographic, 912 vs 3418% (p<0.0001); histomorphometric,
228 vs 5118% (p<0.0001). The injury (0.60.5) and inﬂammation scores
(0.80.3) were uniformly low in all the groups. As a marker of the pharmacologic
effect, we observed lower values of endothelialization rate (8710 vs 992%,
p¼0.0007) and higher ﬁbrin scores (2.10.7 vs 0.40.5, p<0.0001) in all the DEB
groups than in controls.Control Test1, Essential Test2, Mod. Essential In.Pact p (DEBs vs. control)
Angiography
%stenosis 33  18 10  15 8  8 12  12 0.0001
Late loss 1.3  0.5 0.4  0.5 0.3  0.3 0.5  0.4 0.0001
Histology
%stenosis 51  18 20  8 21  6 26  9 0.0001
Neointimal area mm2 3.4  1.2 1.5  0.7 1.7  0.4 1.9  0.8 0.0001
Injury score 0.9  0.6 0.6  0.3 0.5  0.5 0.6  0.6 0.29
Inﬂammation score 0.9  0.2 0.8  0.3 0.8  0.2 0.9  0.4 0.47
% endothelialization 99  1 86  12 84  11 93  4 0.0007
Fibrin score 0.4  0.5 2.3  0.8 2.2  0.5 1.7  0.8 0.0001Conclusions: In this preclinical model, the analyzed DEBs showed a signiﬁcant
reduction in restenosis as compared with control balloons after stent implantation. No
data of increased injury score or persistent inﬂammation was observed, but the
delayed endothelialization and ﬁbrin accumulation suggest a response to the drug
deposition.
TCT-797
Vascular healing after AXERA Access and Closure: a 30 day histopathological
assessment in the ovine model.
Rahul Patel1, Renu Virmani2, Frank D. Kolodgie3, Debra Cogan4
1Mount Sinai Medical Center, New York, NY, 2CVPath Institute, Inc., Gaithersburg,
MD, 3CVPath, Gaithersburg, VA, 4Arstasis, Inc., Redwood City, CA
Background: Conventional Seldinger access has been the standard of care for over 60
years. It is performed at a relatively steep 45 angle that results in relatively high axialB242 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jtension in the artery wall; this in turn theoretically impedes closure of the access site.
A novel technology, AXERA (Arstasis, Redwood City), creates a shallow angle
arteriotomy that signiﬁcantly increases the tissue overlap within the cannulated track.
By taking advantage of the patient's own arterial pressure and the much lower axial
tension, Axera provides a degree of self-sealing. This animal testing was designed to
address whether or not the longer, shallower access track increases risk of dissection
or pseudoaneurysm or potentially impedes healing.
Methods: AXERA and control (Seldinger access) arteriotomy were performed on
contralateral femoral artery vessels in seven sheep. The vessels were examined
histologically 30 days postoperatively after step sectioning through the entire arte-
riotomy site. Histologic sections collected at each level of approximately 200 microns
were stained by H&E and modiﬁed Movat pentachrome.
Results: Creation of the arteriotomy site was successful for both methods in all 14
arteries. There was no evidence of vascular aneurysms or ectasia, medial dissection,
or luminal thrombosis. Vascular healing in both groups was mainly characterized by
transmural deposition of proteoglycan with inﬁltrating smooth muscle cells
accompanied by varying degrees of neoangiogenesis. Inﬂammation was generally
minimal to mild with rare giant cells. Mild to moderate calciﬁcation, mostly
involving the media, was noted in 6 arteries from 4 of 7 animals (3 Axera, 3
control) and is likely inherent to this pre-clinical model of injury. Advanced healing
in both groups was indicated by the absence of ﬁbrin and near complete endothelial
coverage.
Conclusions: The data indicate that healing after AXERA access is similar to standard
Seldinger access technique with no evidence of dissection or pseudoaneurysm. This
study histologically reafﬁrms the safety proﬁle of the Axera device evidenced by the
clinical results of the SECURE II and RECITAL trials.
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Anatomical Effect on Left Atrial After Transcatheter Left Atrial Appendage
Devices: Watchman and Amplatzer Cardiac Plug in a Canine Model
Dongming Hou1, Saibal Kar2, Russell M. Jones3, Dennis Werner4, Lynne Swanson4,
Brian Tischler4, Barbara A. Huibregtse5, Renu Virmani6
1BSCI, Maple Grove, MN, 2David Geffen School of Medicine at UCLA, Los Angeles,
3CVPath, Gaithersburg, MD, 4Boston Scientiﬁc Corporation, arden hills, MN,
5Boston Scientiﬁc Corporation, Marlborough, MA, 6CVPath Institute, Inc.,
Gaithersburg, MD
Background: Watchman (WM, Boston Scientiﬁc, Natick, MA) and Amplatzer
Cardiac Plug (ACP, St. Jude Medical, St. Paul, MN) are the most commonly used
LAA closure devices in patients with non-valvular atrial ﬁbrillation. WM has a para-
chute-shape designed to sit within the ostium of the LAA. The ACP has a disc and
lobe design, utilizing the disc to cover the LAA os. The impact of both devices on
local anatomy as well as healing response following placement ex vivo and in vivo in
a canine model at 28 days was evaluated.
Methods: WM (21mm) and ACP (16mm) devices were implanted in an adult canine
heart ex vivo to evaluate device surface area and conformation to the LAA. Both
devices (n¼3/group) with 10% larger than the LAA os in size were deployed in six
adult dogs under TEE and ﬂuoroscopy guidance and histology analyzed at 28 days.
Results: WM conformed to the LAA os without intrusion of left upper pulmonary
vein (LUPV) and mitral valve (MV), and was seated tightly in the LAA os. Space
from either inferior or superior edges to the MV (inf-to-MV, measured 9.31.2 mm)
and LUPV (sup-to-LUPV) allowed room for ablation. In comparison, the disc of the
ACP clearly extended to both the LUPV and MV. In vivo, the inf-to-MV from the disc
of ACP extended beyond the mitral leaﬂet, and its sup-to-LUPV impinged into the
lateral ridge beneath the LUPV, potentially limiting access for other procedures (eg.
pulmonary vein isolation). On histology, both devices were covered by mature
connective tissue with intermittent areas of early-organized ﬁbrin and thrombus. The
surface of WM inclusive of the threaded insert was completely endothelialized, but the
inferior edge and end-screw hub of the ACP disc were uncovered. WM had a greater
granulation tissue response and less ﬁbrin deposition than ACP, while ACP had
a greater inﬂammatory response.
Conclusions: These data demonstrate that conformation to the LAA and surrounding
structures is different between WM and ACP LAA closure devices, and may have an
effect on and the healing response following placement. Due to the design of the WM
device, it does not obstruct or impact adjacent structures.
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Direct Visualization of Pulmonary Vein Ablations within Reanimated Swine
Hearts to Investigate Recent Advances in Cryo-balloon Technologies
Ryan P. Goff1, Wyn Davies2, Mark A. Benscoter1, Stephen A. Howard1,
Paul A. Iaizzo1
1University of Minnesota, Minneapolis, MN, 2St. Mary's Hospital, Imperial College
Healthcare NHS Trust, London, United Kingdom
Background: The use of cryo-balloon ablation for pulmonary vein (PV) isolation has
led to questions as to how best to optimize single procedure success. Speciﬁcally,
what new indicators can be identiﬁed to better determine ideal ablation durations as
well as the best catheter orientations and catheter placements in the PV antra. Here we
present unique data obtained by observing PV antral cryo-balloon ablation under
direct vision.TCT Abstracts/POSTER/Basic Science, Animal Models, and Cell Therapy
